One study reported that in basal-like breast cancer (BLBC), the activation of nuclear factor кB (NF-кB) could suppress TET1 by binding to its promoter, highlighting a novel epigenetic-immunity connection (Collignon et al., 2018). Here, TET1 is linked to breast carcinoma.